A study presented at the San Antonio Breast Cancer Symposium examined whether tumor mutational burden (TMB) was associated with outcomes in hormone receptor-positive, HER2-negative metastatic breast ...
Alpelisib, we ran into a lot of toxicities, but they were all alpelisib toxicities. So a lower dose will be tested in the next cohort with elacestrant. And then capivasertib [Truqap] is in the early ...